Attach to Form 990 or Form 990-EZ.
Go to
www.irs.gov/Form990 for instructions and the latest information.
| (i) Name of supported organization | (ii) EIN | (iii) Type of organization (described on lines 1- 10 above (see instructions)) | (iv) Is the organization listed in your governing document? | (v) Amount of monetary support (see instructions) | (vi) Amount of other support (see instructions) | |
|---|---|---|---|---|---|---|
| Yes | No | |||||
|
Total |
||||||
Calendar year
(or fiscal year beginning in)
![]() |
(a) 2019 | (b) 2020 | (c) 2021 | (d) 2022 | (e) 2023 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 1 | Gifts, grants, contributions, and membership fees received. (Do not include any "unusual grant.") .. | ||||||
| 2 | Tax revenues levied for the organization's benefit and either paid to or expended on its behalf .... | ||||||
| 3 | The value of services or facilities furnished by a governmental unit to the organization without charge.. | ||||||
| 4 | Total. Add lines 1 through 3 | ||||||
| 5 | The portion of total contributions by each person (other than a governmental unit or publicly supported organization) included on line 1 that exceeds 2% of the amount shown on line 11, column (f) .. | ||||||
| 6 | Public support. Subtract line 5 from line 4. | ||||||
Calendar year
(or fiscal year beginning in)
![]() |
(a) 2019 | (b) 2020 | (c) 2021 | (d) 2022 | (e) 2023 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 7 | Amounts from line 4.. | ||||||
| 8 | Gross income from interest, dividends, payments received on securities loans, rents, royalties and income from similar sources... | ||||||
| 9 | Net income from unrelated business activities, whether or not the business is regularly carried on.. | ||||||
| 10 | Other income. Do not include gain or loss from the sale of capital assets (Explain in Part VI.).. | ||||||
| 11 | Total support. Add lines 7 through 10 | ||||||
Calendar year (or fiscal
year beginning in) ![]() |
(a) 2019 | (b) 2020 | (c) 2021 | (d) 2022 | (e) 2023 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 1 | Gifts, grants, contributions, and membership fees received. (Do not include any "unusual grants.") . | 1,309,052 | 3,667,190 | 657,669 | 3,106,327 | 1,077,725 | 9,817,963 |
| 2 | Gross receipts from admissions, merchandise sold or services performed, or facilities furnished in any activity that is related to the organization's tax-exempt purpose | ||||||
| 3 | Gross receipts from activities that are not an unrelated trade or business under section 513 ..... | ||||||
| 4 | Tax revenues levied for the organization's benefit and either paid to or expended on its behalf... | ||||||
| 5 | The value of services or facilities furnished by a governmental unit to the organization without charge | ||||||
| 6 | Total. Add lines 1 through 5 | 1,309,052 | 3,667,190 | 657,669 | 3,106,327 | 1,077,725 | 9,817,963 |
| 7a | Amounts included on lines 1, 2, and 3 received from disqualified persons | 0 | |||||
| b | Amounts included on lines 2 and 3 received from other than disqualified persons that exceed the greater of $5,000 or 1% of the amount on line 13 for the year. | 0 | |||||
| c | Add lines 7a and 7b.. | 0 | |||||
| 8 | Public support. (Subtract line 7c from line 6.) | 9,817,963 | |||||
Calendar year
(or fiscal year beginning in)
![]() |
(a) 2019 | (b) 2020 | (c) 2021 | (d) 2022 | (e) 2023 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 9 | Amounts from line 6... | 1,309,052 | 3,667,190 | 657,669 | 3,106,327 | 1,077,725 | 9,817,963 |
| 10a | Gross income from interest, dividends, payments received on securities loans, rents, royalties and income from similar sources.. | 818 | 3,318 | 16,481 | 22,726 | 32,384 | 75,727 |
| b | Unrelated business taxable income (less section 511 taxes) from businesses acquired after June 30, 1975. | ||||||
| c | Add lines 10a and 10b. | 818 | 3,318 | 16,481 | 22,726 | 32,384 | 75,727 |
| 11 | Net income from unrelated business activities not included on line 10b, whether or not the business is regularly carried on. | 25,823 | 25,823 | ||||
| 12 | Other income. Do not include gain or loss from the sale of capital assets (Explain in Part VI.) .. | ||||||
| 13 | Total support. (Add lines 9, 10c, 11, and 12.).. | 1,309,870 | 3,696,331 | 674,150 | 3,129,053 | 1,110,109 | 9,919,513 |
| Section A - Adjusted Net Income | (A) Prior Year |
(B) Current Year (optional) |
||||
| 1 | Net short-term capital gain | 1 | ||||
| 2 | Recoveries of prior-year distributions | 2 | ||||
| 3 | Other gross income (see instructions) | 3 | ||||
| 4 | Add lines 1 through 3 | 4 | ||||
| 5 | Depreciation and depletion | 5 | ||||
| 6 | Portion of operating expenses paid or incurred for production or collection of gross income or for management, conservation, or maintenance of property held for production of income (see instructions) | 6 | ||||
| 7 | Other expenses (see instructions) | 7 | ||||
| 8 | Adjusted Net Income (subtract lines 5, 6 and 7 from line 4) | 8 | ||||
| Section B - Minimum Asset Amount | (A) Prior Year |
(B) Current Year (optional) |
||||
| 1 | Aggregate fair market value of all non-exempt-use assets (see instructions for short tax year or assets held for part of year): | 1 | ||||
| a | Average monthly value of securities | 1a | ||||
| b | Average monthly cash balances | 1b | ||||
| c | Fair market value of other non-exempt-use assets | 1c | ||||
| d | Total (add lines 1a, 1b, and 1c) | 1d | ||||
| e |
Discount claimed for blockage or other factors (explain in detail in Part VI): |
|||||
| 2 | Acquisition indebtedness applicable to non-exempt use assets | 2 | ||||
| 3 | Subtract line 2 from line 1d | 3 | ||||
| 4 | Cash deemed held for exempt use. Enter 0.015 of line 3 (for greater amount, see instructions). | 4 | ||||
| 5 | Net value of non-exempt-use assets (subtract line 4 from line 3) | 5 | ||||
| 6 | Multiply line 5 by 0.035 | 6 | ||||
| 7 | Recoveries of prior-year distributions | 7 | ||||
| 8 | Minimum Asset Amount (add line 7 to line 6) | 8 | ||||
| Section C - Distributable Amount | Current Year | |||||
| 1 | Adjusted net income for prior year (from Section A, line 8, Column A) | 1 | ||||
| 2 | Enter 85% of line 1 | 2 | ||||
| 3 | Minimum asset amount for prior year (from Section B, line 8, Column A) | 3 | ||||
| 4 | Enter greater of line 2 or line 3 | 4 | ||||
| 5 | Income tax imposed in prior year | 5 | ||||
| 6 | Distributable Amount. Subtract line 5 from line 4, unless subject to emergency temporary reduction (see instructions) | 6 | ||||
| Section D - Distributions | Current Year | |
|---|---|---|
| 1 Amounts paid to supported organizations to accomplish exempt purposes | 1 | |
|
2
Amounts paid to perform activity that directly furthers exempt purposes of supported organizations, in excess of income from activity |
2 | |
| 3 Administrative expenses paid to accomplish exempt purposes of supported organizations | 3 | |
| 4 Amounts paid to acquire exempt-use assets | 4 | |
| 5 Qualified set-aside amounts (prior IRS approval required - provide details in Part VI) | 5 | |
| 6 Other distributions (describe in Part VI). See instructions | 6 | |
| 7Total annual distributions. Add lines 1 through 6. | 7 | |
|
8
Distributions to attentive supported organizations to which the organization is responsive (provide details in Part VI). See instructions |
8 | |
| 9 Distributable amount for 2023 from Section C, line 6 | 9 | |
| 10 Line 8 amount divided by Line 9 amount | 10 | |
| Section E - Distribution Allocations (see instructions) |
(i) Excess Distributions |
(ii) Underdistributions Pre-2023 |
(iii) Distributable Amount for 2023 |
|
|---|---|---|---|---|
| 1 Distributable amount for 2023 from Section C, line 6 | ||||
|
2
Underdistributions, if any, for years prior to 2023 (reasonable cause required-- explain in Part VI).
See instructions. |
||||
| 3 Excess distributions carryover, if any, to 2023: | ||||
| a From 2018....... | ||||
| b From 2019....... | ||||
| c From 2020....... | ||||
| d From 2021....... | ||||
| e From 2022....... | ||||
| fTotal of lines 3a through e | ||||
| g Applied to underdistributions of prior years | ||||
| h Applied to 2023 distributable amount | ||||
|
i
Carryover from 2018 not applied (see instructions) |
||||
| j Remainder. Subtract lines 3g, 3h, and 3i from line 3f. | ||||
| 4Distributions for 2023 from Section D, line 7: | ||||
| $ | ||||
| a Applied to underdistributions of prior years | ||||
| b Applied to 2023 distributable amount | ||||
| c Remainder. Subtract lines 4a and 4b from line 4. | ||||
|
5
Remaining underdistributions for years prior to 2023, if any. Subtract lines 3g and 4a from line 2. If the amount is greater than zero, explain in Part VI. See instructions. |
||||
|
6
Remaining underdistributions for 2023. Subtract lines 3h and 4b from line 1. If the amount is greater than zero, explain in Part VI. See instructions. |
||||
|
7 Excess distributions carryover to 2024. Add lines 3j and 4c. |
||||
| 8 Breakdown of line 7: | ||||
| a Excess from 2019..... | ||||
| b Excess from 2020..... | ||||
| c Excess from 2021..... | ||||
| d Excess from 2022..... | ||||
| e Excess from 2023..... | ||||
| Facts And Circumstances Test |
|---|
| Return Reference | Explanation |
|---|
| Software ID: | |
| Software Version: |
| Return Reference | Explanation |
|---|---|
| FORM 990, PART I, LINE 1, DESCRIPTION OF ORGANIZATION MISSION: | CREATED IN 2009. ORIGINALLY, THE MISSION OF THE CORPORATION WAS TO COLLABORATE WITH CARDIOVASCULAR LEADERS IN AFRICA TO IMPROVE THE EARLY DIAGNOSIS AND TREATMENT OF CARDIOVASCULAR DISEASES AND HEART FAILURE IN SUB-SAHARAN AFRICA, PARTICULARLY INCREASING USAGE OF PROVEN THERAPIES FOR HEART FAILURE AND IMPROVE ADHERENCE. THROUGH THE COURSE OF ITS WORK, THE CORPORATION'S ACTIVITIES AND RESEARCH HAVE EVOLVED. THE CORPORATION HAS PARTNERED WITH MOMENTUM RESEARCH, INC., LARIBOISIRE HOSPITAL IN PARIS, AND ROCHE DIAGNOSTICS TO EXAMINE OTHER ASPECTS OF EARLY DIAGNOSIS AND TREATMENT OF CARDIOVASCULAR DISEASE, SPECIFICALLY HEART FAILURE, BEYOND AFRICA. MISSION AND ACCOMPLISHMENTS: DURING 2023 THE HEART INITIATIVE CONTINUED ITS SCIENTIFIC MISSION TO IMPROVE HEART FAILURE THERAPY GLOBALLY THROUGH TWO MAIN AVENUES: 1. PUBLICATIONS AND SHARING OF DATA FROM STUDIES COMPLETED THE HEART FROM STUDIES COMPLETED IN 2022 AND PREVIOUS YEARS AND SHARE THEM WITH THE SCIENTIFIC COMMUNITY. SUCH EXAMPLES ARE HIGHLIGHTED IN THE LINKS BELOW AMONG THE CONTRIBUTING MEMBERS OF OUR RESEARCH ORGANIZATION. HTTPS://PUBMED.NCBI.NLM.NIH.GOV/36356631/ 2. PERFORMING STUDIES TO PROMOTE BETTER HEART HEALTH GLOBALLY, THE HEART INITIATIVE HAS CONTINUED TO SPONSOR ITS LARGEST STUDY TO DATE THE STRONG-HF STUDY WHICH IS AIMED AT BETTER IMPLEMENTING CHEAP, GENERIC THERAPIES IN PATIENTS AFTER AND ADMISSION TO A HOSPITAL FOR HEART FAILURE. IN 2022, THE HEART INITIATIVE SECURED ADDITIONAL SPONSORSHIP FROM ROCHE DIAGNOSTICS TO ENABLE EXPANDING THE STUDY TO UP TO 1,100 PATIENTS AND CONTINUES TO RECRUIT PATIENTS TO THE STUDY GLOBALLY IN EUROPE, SOUTH AMERICA AND SUBSAHARAN AFRICA. IN 2022, THE STUDY WAS COMPLETED AND ANALYZED, PRESENTED AND PUBLISHED. 3. THE HEART INITIATIVE AS WITH ITS PARTNERS AT ISNERM HAVE INITIATED A NEW STUDY TO EXPLORE THE EFFECTS OF STEROIDS IN AHF. THE STUDY TITLE IS "EFFECT OF SHORT-TERM PREDNISONE THERAPY ON C-REACTIVE PROTEIN CHANGE IN EMERGENCY DEPARTMENT PATIENTS WITH ACUTE HEART FAILURE AND ELEVATED INFLAMMATORY MARKERS" ACUTE HEART FAILURE (AHF) IS A COMMON DISCHARGE DIAGNOSIS IN THE EMERGENCY DEPARTMENT (ED), ASSOCIATED WITH 1-MONTH MORTALITY OF 6%, AND A 30% RISK RATE OF 1-MONTH REHOSPITALIZATION. CURRENT GUIDELINES RECOMMEND THE USE OF NITRATES AND LOW DOSE DIURETIC TO TREAT CONGESTION, BUT TO DATE, NO DRUG HAS EVER SHOWN ANY IMPROVED CLINICAL OUTCOME WHEN GIVEN AT THE ACUTE PHASE. SEVERAL STUDIES SUGGEST THAT THERE IS A HIGH INFLAMMATORY COMPONENT IN AHF, WITH ELEVATED MARKERS SUCH AS IL6 AND C-REACTIVE PROTEIN (CRP). AS IT IS THE CASE IN OTHER ACUTE RESPIRATORY DISEASE, A SHORT COURSE OF STEROID THERAPY MAY LIMIT THE INFLAMMATORY RESPONSE AND IN TURN, IMPROVE AHF PROGNOSIS. THE OBJECTIVE OF THE STUDY IS TO ASSESS THE EFFECT OF A 7-DAY COURSE OF STEROID INTRODUCED IN THE ED ON INFLAMMATORY RESPONSE. THE STUDY IS A PARALLEL-GROUP, RANDOMIZED, OPEN-LABEL, CONTROLLED TRIAL IN 5 EDS IN FRANCE. PATIENTS WITH AHF AND HIGH CRP LEVELS WILL BE RANDOMIZED TO 7 DAYS OF PREDNISONE THERAPY OR CONTROL AND FOLLOWED FOR 30DAYS. ENDPOINTS INCLUDE CHANGE IN CRP LEVELS AND RISK OF WORSENING HF, HF READMISSION OR DEATH TO DAY 30. 4. THE HEART INITIATIVE AND ITS PARTNERS IN MOUNT SINAI HOSPITAL IN NYC HAVE INITIATED A STUDY TO ASSESS WAYS TO IMPROVE ADHERENCE IN PATIENTS WITH HTN AND HYPERLIPIDEMIA. THE STUDY ENTILTLED: "CP&R - CARDIOVASCULAR PRECISION MEDICINE & REMOTE INTERVENTION". CONTROL OF HYPERTENSION AND HYPERCHOLESTEROLEMIA IS KEY TO REDUCING RISK OF ADVERSE CARDIOVASCULAR OUTCOMES IN PATIENTS WITH CARDIOVASCULAR MORBIDITY. NON-ADHERENCE TO MEDICAL RECOMMENDATIONS IS THE MOST IMPORTANT REASON FOR ADVERSE OUTCOMES, AS BLOOD PRESSURE REMAINS ERRATIC IF MEDICATION-TAKING IS ALSO ERRATIC. NON-ADHERENCE CAN BE IDENTIFIED BY MULTIPLE SUBJECTIVE AND OBJECTIVE METHODS, BUT SUBJECTIVE METHODS (PATIENTS' OWN REPORTS) ARE NOT RELIABLE, AND OBJECTIVE METHODS MAY BE MISLEADING (IF THEY ARE DEPENDENT ON FACTORS OTHER THAN ADHERENCE), OR CUMBERSOME. FOR EXAMPLE, ELECTRONIC MONITORING OF ADHERENCE TENDS TO REQUIRE THE USE OF A SPECIFIC DEVICE, AND THE MOST NON-ADHERENT PATIENTS TEND NOT TO BE ABLE TO CONSISTENTLY USE THE DEVICE, RESULTING IN STUDY DESIGNS THAT FAVOR ADHERENT PATIENTS (IN STUDIES THAT PURPORT TO IMPROVE ADHERENCE). THE PRESENT STUDY USES A NOVEL INDICATOR FOR NON-ADHERENCE BASED ON ELECTRONIC HEALTH RECORD (EHR) DATA: THE DEGREE OF VARIABILITY OF BLOOD PRESSURE MEASUREMENTS OVER TIME. RISK STRATIFICATION BY A VARIABILITY MARKER WILL BE COUPLED WITH REMOTE INTERVENTION OFFERED ONLY TO PATIENTS WHO ARE AT INCREASED RISK. THE INTERVENTION WILL BE TARGETED AT THE POSSIBLE ROOT CAUSES OF THESE PATIENTS' NON-ADHERENCE. THE INNOVATIONS IN OUR APPROACH ARE THE USE OF A MARKER DERIVED FROM EHR INFORMATION TO TARGET THE INTERVENTION (RESULTING IN BETTER RESOURCE ALLOCATION), THE REMOTE INTERVENTION THAT DOES NOT REQUIRE IN-PERSON MEETINGS WHICH MAY BE HARD TO IMPLEMENT ESPECIALLY WITH PATIENTS WHO ARE NON-ADHERENT TO THEIR MEDICAL RECOMMENDATIONS ANYWAY, AND THE FLEXIBLE AND ADAPTABLE INTERVENTION THAT IS CUSTOMIZED FOR EACH PATIENT. 5. THE HEART INITIATIVE INITIATED A NEW STUDY, ROBUST HF, WHICH WILL HELP IMPLEMENT THE RESULTS OF STRONG HF GLOBALLY. THE STUDY WAS THE MAIN FOCUS OF THE HEART INITIATIVE IN 2023. |
| FORM 990, PART VI, SECTION A, LINE 2 | GAD COTTER AND BETH COTTER-DAVIDSON ARE DIRECTORS AND MARRIED TO EACH OTHER. |
| FORM 990, PART VI, SECTION B, LINE 11B | NO REVIEW WAS OR WILL BE CONDUCTED. |
| FORM 990, PART VI, SECTION C, LINE 19 | NO OTHER DOCUMENTS AVAILABLE TO THE PUBLIC. |
| FORM 990, PART IX, LINE 11G | PROFESSIONAL FEES: PROGRAM SERVICE EXPENSES 2,408,919. MANAGEMENT AND GENERAL EXPENSES 0. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 2,408,919. |
| Software ID: | |
| Software Version: |